ClinicalTrials.gg
Not yet recruitingNCT07748975DETAILUpdated Nov 20, 2026

Decode the Environment Variation of Targeted Aldosterone Inducer and siLencer

An interventional study of Aldosterone circulation and Medication in Hypertension, Aldosteronemia and CYP11B1, sponsored by DejthidaNathaphong. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by DejthidaNathaphong · Not applicable, Interventional, and Screening

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Hypertension with a site in Thailand — 7 open to participants now, 14 under way, 4 of them phase 3. Hypertension · Thailand.

Planned enrollment
27th of 34
100 · median 325
Started
2026
with 2 others
No phase
14 of 46
3 open now
Primary completion
2027-02
later than 8 of 13 live
Registered
44th of 46
by date
Lead sponsor
4 of 46
DejthidaNathaphong

Among the 46 studies in Hypertension with a site in Thailand, this one is the 27th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 44th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

7 of the 46 studies in Hypertension with a site in Thailand are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Hypertension with a site in Thailand, or all of them as a file.
02

Study summary

Clinical outcome to identify and analyze the epigenetic, phenotypic, protein variation, metabolites of CYP450 Family 11 Subfamily B, both 1 and 2, human-associated aldosterone protein release, and signaling inhibitory pathways post-aldosterone-mineralocorticoid interaction.

We will include clinical studies (RCTs, cohort, case-control/series/report) from fresh human specimens. We will exclude animal studies, studies generated from cell culture, and aldosterone synthesis.

To systematically review and synthesize the literature on the main 2 questions Question 1: Which environment induces CYP11B1 or CYP11B2 activation causing hyperaldosteronemia in hypertension patients? Question 2: Which intracellular signal silences aldosterone-MR activity? For Individual Participant Data Meta-analysis, data will be extracted from final analysis articles from the framework of the data selection process only; the effect measurement and multi-variable model meta-analysis will be performed.

Primary Objective1: to identify CYP450 Family 11 Subfamily B and Aldosterone in hypertension patients following; By structure ● Evidence confirms Epigenetic profile of CYP450 Family 11 Subfamily B, Aldosterone, Signal in hypertension patients, both random and treated from any DNA sequencing method Protein synthesis evidence of aldosterone protein induces hypertension from Western blot or LC-MS By function Metabolomic profile: the substrate or product refers to aldosterone interaction causing end-organ cell line dysfunction or impaired structure.

Inhibitory signaling profiling of hypertension patients compared to non-hypertension patients, which negatively feedback to CYP450 Family 11 Subfamily B or Aldosterone

Secondary Objective 2:

Sub-group analysis effect measurement following;

  • Proposed mechanisms, biological markers, or pathways that contribute to failure to regulate aldosteronemia
  • Treatment-related permanent normotensive post-hyperaldosteronemia. Primary Objective 2: Identify possible intracellular signal inhibit aldosterone action
  • Analyze possible mechanisms of signal that are silent aldosterone-MR activity
  • Differentiation of free aldosterone and attached aldosterone

Secondary Objective 2:

● Sensitivity and specificity of outcomes of hypertension patients who underwent estimate substrate associated aldosterone circulation Plasma CYP450 Family 11 Subfamily B Urine CYP450 Family 11 Subfamily B Plasma Aldosterone (active form) Plasma Aldosterone (metabolite form) Urine Aldosterone

Read the detailed description

Primary Objective1: to identify CYP450 Family 11 Subfamily B and Aldosterone in hypertension patients following; By structure ● Evidence confirms Epigenetic profile of CYP450 Family 11 Subfamily B, Aldosterone, Signal in hypertension patients, both random and treated from any DNA sequencing method Protein synthesis evidence of aldosterone protein induces hypertension from Western blot or LC-MS By function Metabolomic profile: the substrate or product refers to aldosterone interaction causing end-organ cell line dysfunction or impaired structure.

Inhibitory signaling profiling of hypertension patients compared to non-hypertension patients, which negatively feedback to CYP450 Family 11 Subfamily B or Aldosterone

Secondary Objective 2:

Sub-group analysis effect measurement following;

  • Proposed mechanisms, biological markers, or pathways that contribute to failure to regulate aldosteronemia
  • Treatment-related permanent normotensive post-hyperaldosteronemia. Primary Objective 2: Identify possible intracellular signal inhibit aldosterone action
  • Analyze possible mechanisms of signal that are silent aldosterone-MR activity
  • Differentiation of free aldosterone and attached aldosterone

Secondary Objective 2:

● Sensitivity and specificity of outcomes of hypertension patients who underwent estimate substrate associated aldosterone circulation Plasma CYP450 Family 11 Subfamily B Urine CYP450 Family 11 Subfamily B Plasma Aldosterone (active form) Plasma Aldosterone (metabolite form) Urine Aldosterone Axin-CK1-GSK3-APC-Beta-catenin complex

03

Conditions studied

  • Hypertension
  • Aldosteronemia
  • CYP11B1
  • CYP11B2
  • Aldosterone Synthase
  • Beta-catenin

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Human birth in all sex chromosomes; evidence of systemic arterial hypertension, both treated and untreated.
  • Evidence of living with owned systemic/arterial hypertension by one of the following;
  • Quantitative: Blood pressure number higher than the normal range by each protocol in mmHg unit in any arm of study.
  • Qualitative: Clarify whether both retrospective, observational, or intervention study of blood pressure, and clearly clarify the number of hypertension participants in the article.

Exclusion criteria

Exclusion Criteria:

  • Under 18 years old
  • Specimens of studies not from humans or human specimens but not from an actual living hypertension patient, such as cell culture, in vitro synthesis from laboratory synthesis
  • No evidence of hypertension in the main study
  • Study of imaging confirms adrenal tumor in all types of histopathology results.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Hypertensive Hyperaldosteronemia

    Diagnostic Test: Aldosterone circulation · Drug: Medication · Procedure: Operation

  • Active comparator
    Hypertensive normoaldosteronemia

    Diagnostic Test: Aldosterone circulation · Drug: Medication · Procedure: Operation

Interventions

  • Diagnostic testAldosterone circulation

    Evidence of synthesis of aldosterone and/or degradation of inactive forms of aldosterone, which focuses on * CYP450 Family 11 Subfamily B * Aldosterone protein * Beta-catenin * Axin-CK1-GSK3-APC complex

  • Medical treatment that interferes with free aldosterone levels and reports systolic blood pressure deviation

  • ProcedureOperation

    The non-medical intervention includes MIS, Open surgery, and intravascular guide treatment aim to treat hypetension and lower aldosterone level.

06

What researchers measure

Primary outcomes

  1. Aldosterone circulation profile

    The result, both qualitative and quantitative, from aldosterone synthesis to degradation and elimination via urine.

    Time frame: 12 months

  2. Aldoseterone synthesis profile

    Focus on both quantitative and qualitative evidence of aldosterone, CYP11B1, andand CYP11B2 protein

    Time frame: 12 months

Secondary outcomes

  1. Degradation Profile

    Focus on the ratio of degradation activity of the inactive form of aldosterone and the inhibitory competitor inhibits the cell product from the aldosterone-mineralocorticoid receptor. Axin-CK1-GSK3-APC complex profile is indicated

    Time frame: 12 months

07

Study locations

1 site
  • Investigation Center
    Vadhana, Bangkok 10110, Thailand
    • Nathaphong Dejthida, Medical Degree · Contactbnnatto@gmail.com · +66819220662
    • · Contactbnnatto@gmail.com
    • Nathaphong Dejthida, Medical Degree · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The recruitment is published data already

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 2 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, last on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Aug 6, 2026
StartEst.
Dec 10, 2026was Aug 2026
Primary completionEst.
Feb 10, 2027
CompletionEst.
Feb 5, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 10, 2026→Dec 10, 2026
moved 2 times, Oct 1, 2026 – Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Start date Oct 10, 2026→Dec 10, 2026
    + 1 other change: verification date
  2. Oct 1, 2026
    Start date Aug 10, 2026→Oct 10, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07748975
Lead sponsor
DejthidaNathaphong
Responsible party
Nathaphong Dejthida (Principal Investigator, DejthidaNathaphong) — Principal investigator
First posted
Aug 6, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
Feb 10, 2027 (estimated)
Completion
Feb 5, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Nathaphong Dejthida, Medical Degree
Contact
bnnatto@gmail.com
+66819220662

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Medication

Start the discussion